Evidence map›Paper›PMID 30458058›Full record

ReviewInternational journal of cancer2019

Fecal microbiota transplantation in cancer management: Current status and perspectives.

Danfeng Chen, Jingyi Wu, Duochen Jin, Bangmao Wang, Hailong Cao

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05502913 (Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Metastatic Lung Cancer), which is not on this map. Cited by 201 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
201citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05502913 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Metastatic Lung Cancer

TypeinterventionalSponsorSoroka University Medical CenterRan2023 to 2028Enrolled80ConditionsMetastatic Lung CancerArmsAntibiotics, FMT (Fecal Microbiota Transplantation)
3 · Its place in the literature

Who cites it

201 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. [Fecal Microbiota Transplantation: A Promising Avenue for Lung Cancer Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

141 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Danfeng ChenDepartment of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin, China.ORCID 0000-0001-8567-5370
Jingyi WuDepartment of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin, China.
Duochen JinDepartment of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin, China.
Bangmao WangDepartment of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin, China.ORCID 0000-0003-2796-1584
Hailong CaoDepartment of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin, China.

Funding

National Natural Science Foundation of China 81570478National Natural Science Foundation of China 81741075Tianjin Research Program of Application Foundation and Advanced Technology of China 17JCYBJC24900
6 · The paper itself

Abstract

The human gut is home to a large and diverse microbial community, comprising about 1,000 bacterial species. The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations with therapeutic intent has become a hot topic of cancer research, and the most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT) from healthy individuals to patients. FMT has demonstrated remarkable clinical efficacy against Clostridium difficile infection (CDI) and it is highly recommended for the treatment of recurrent or refractory CDI. Lately, interest is growing in the therapeutic potential of FMT for other diseases, including cancers. We briefly reviewed the current researches about gut microbiota and its link to cancer, and then summarized the recent preclinical and clinical evidence to indicate the potential of FMT in cancer management as well as cancer-treatment associated complications. We also presented the rationale of FMT for cancer management such as reconstruction of intestinal microbiota, amelioration of bile acid metabolism, and modulation of immunotherapy efficacy. This article would help to better understand this new therapeutic approach for cancer patients by targeting gut microbiota.

Indexed as

Clostridioides difficileClostridium InfectionsDysbiosisFecal Microbiota TransplantationFecesGastrointestinal MicrobiomeHumansMicrobiotaNeoplasmsTreatment Outcomecancerdysbiosisfecal microbiota transplantationgut microbiotatherapy

Identifiers

PMID30458058
PMCPMC6767494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.